Abstract | PURPOSE: METHODS: We retrospectively studied 42 eyes with PNV and 60 eyes with Type 1 neovascular AMD. We assessed best-corrected visual acuity (BCVA), central macular thickness (CMT), central choroidal thickness (CCT), and total number of injections over 2 years. RESULTS: The BCVA and CMT improvements during the 2-year treatment period did not differ significantly between PNV and AMD; however, CCT decreased significantly in PNV than in AMD (P<0.05). Management of PNV required significantly fewer injections than AMD during the 2-year period (P<0.05). There were no significant differences in BCVA, CMT and CCT changes between PNV with and without polypoidal lesions (28 vs. 14 eyes) during the 2 year period. Significantly fewer injections were needed for PNV with polypoidal lesions than for PNV without (P<0.01). There were no significant differences in BCVA, CMT and CCT changes, or in the number of injections during the 2-year treatment period, between AMD with and without polypoidal lesions (30 vs. 30 eyes). CONCLUSION: Treat-and-extend regimen of intravitreal aflibercept injection may be equally effective in terms of improvement of BCVA and exudative changes both in eyes with PNV and those with Type 1 neovascular AMD requiring fewer injections for the former. Among eyes with PNV, those with polypoidal lesions needed fewer injections than those without polypoidal lesions.
|
Authors | Hidetaka Matsumoto, Takashi Hiroe, Masahiro Morimoto, Kensuke Mimura, Arisa Ito, Hideo Akiyama |
Journal | Japanese journal of ophthalmology
(Jpn J Ophthalmol)
Vol. 62
Issue 2
Pg. 144-150
(Mar 2018)
ISSN: 1613-2246 [Electronic] Japan |
PMID | 29411171
(Publication Type: Journal Article)
|
Chemical References |
- Recombinant Fusion Proteins
- aflibercept
- Receptors, Vascular Endothelial Growth Factor
|
Topics |
- Aged
- Choroid
(blood supply, diagnostic imaging)
- Choroidal Neovascularization
(diagnosis, drug therapy, physiopathology)
- Drug Administration Schedule
- Female
- Fluorescein Angiography
- Follow-Up Studies
- Fundus Oculi
- Humans
- Intravitreal Injections
- Macula Lutea
(pathology)
- Macular Degeneration
(diagnosis, drug therapy, physiopathology)
- Male
- Receptors, Vascular Endothelial Growth Factor
(administration & dosage, antagonists & inhibitors)
- Recombinant Fusion Proteins
(administration & dosage)
- Retrospective Studies
- Time Factors
- Tomography, Optical Coherence
- Treatment Outcome
- Visual Acuity
|